Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610478 | 0.84 | HCRTR1 (0.45) | HCRTR1HCRTR2KCNH2CCR2 | |
| SCHEMBL2610476 | 0.83 | HCRTR1 (0.40) | HCRTR1HCRTR2KCNH2HTR2AHTR2C | |
| SCHEMBL2610468 | 0.81 | HCRTR1 (0.41) | HCRTR1HCRTR2KCNH2HTR2AHTR2C | |
| SCHEMBL2610456 | 0.81 | HCRTR1 (0.48) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610457 | 0.75 | HTR2A (0.43) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL22666389 | 0.72 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL29521573 | 0.72 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL19124706 | 0.72 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2116673 | 0.72 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610688 | 0.69 | HCRTR1 (0.52) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885KCNH2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.